HEAD-TO-HEAD

MAZDUTIDE VS SURVODUTIDE

Mazdutide and survodutide are two parallel GLP-1 + glucagon dual receptor agonists in late-stage development, by different sponsors. Mazdutide (IBI362, Innovent Biologics under license from Eli Lilly) is in Phase 3 GLORY in China. Survodutide (BI 456906, Boehringer Ingelheim / Zealand) is in Phase 3 SYNCHRONIZE globally. Different molecules, similar mechanism, different regulatory geography.

A · No. 021HP 190

MAZDUTIDE

GLP-1 + Glucagon · Innovent

B · No. 019HP 195

SURVODUTIDE

GLP-1 + Glucagon Dual Agonist

SIDE BY SIDE

FIELD

A · MAZDUTIDE

B · SURVODUTIDE

Class

GLP-1 + glucagon dual agonist

Development code

IBI362 / LY3305677

BI 456906

Sponsor

Innovent Biologics (CN) under Lilly license

Boehringer Ingelheim / Zealand Pharma

Half-life

~7 days (once-weekly)

Best Phase 2 outcome

-11.1% placebo-subtracted BW at 9 mg/wk, 24 wk (Zhao 2024 Chinese Phase 2)

-14.9% placebo-subtracted BW at 4.8 mg/wk, 46 wk (Le Roux 2024 Lancet D&E)

Phase 3 status

Phase 3 GLORY-1 met primary endpoint in Chinese adults; NMPA review ongoing

Phase 3 SYNCHRONIZE-1 / SYNCHRONIZE-2 enrolling

Regulatory geography

China-first; not FDA-approved

Global investigational; not FDA-approved

WADA status

Not listed (2026)

WHICH IS BETTER · BY GOAL

▶ China-population dataA · MAZDUTIDE

Mazdutide has dedicated Chinese-population Phase 2 and Phase 3 data (Zhao 2024 Phase 2 in Chinese adults; GLORY-1 met primary endpoint). Survodutide global Phase 2 was multi-region.

▶ NASH / liver-fat researchB · SURVODUTIDE

Survodutide Phase 2 (Sanyal 2024 NEJM) reported improved liver fat and histology endpoints. Mazdutide NASH data not yet published at equivalent depth.

▶ Western regulatory pathwayB · SURVODUTIDE

Survodutide Phase 3 SYNCHRONIZE program is enrolling for global / Western approval. Mazdutide pathway is China-first via NMPA.

▶ Placebo-subtracted weight loss headline numberB · SURVODUTIDE

Survodutide 4.8 mg/wk reached -14.9% at 46 weeks. Mazdutide 9 mg/wk reached -11.1% at 24 weeks. Trial durations differ but the survodutide arm produced a larger absolute number.

STACKING NOTE

No published research stacks two GLP-1/glucagon dual agonists. They engage the same receptor pair; combined use is unstudied. Buyers researching the dual-agonist category typically order both as parallel reference compounds.

SOURCED FROM PEPPU LABS

Both compounds are available as research-grade material at Peppu Studio · ≥99% purity · per-batch CoA. For laboratory research use only.

SOURCE MAZDUTIDE ▶SOURCE SURVODUTIDE ▶